Last update 21 Nov 2024

Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

TAA5 bsAb(PersonGen Biotherapeutics)

Target

CTLA4 x c-Met

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Active Organization

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

100 Clinical Results associated with Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

100 Translational Medicine associated with Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

100 Patents (Medical) associated with Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

330

Literatures (Medical) associated with Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

01 Dec 2024·Medical Microbiology and Immunology

Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses

Article

Author: Li, Yue-Zhou ; Bostina, Mihnea ; Qu, Xiaowang ; Liu, Yong-Chen ; Liu, Wenpei ; Pan, Zhendong ; Wu, Qian ; Chang, Fangfang ; Hu, Yabin ; Li, Yi-Ping ; Zhao, Ping

The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). A bsAb 5-HI showed a high binding capability to the S1 subunit of spike and exhibited breadth and potency against pseudotyped SARS-CoV-2 variants of concerns (VOCs) and SARS-related-CoVs (SARSr-CoVs), with half maximal effective concentration (EC₅₀) of 0.028-3.444 nM and 50% inhibitory concentration (IC₅₀) of 0.008-0.800 nM. In addition, it retained neutralization potency against the peudotyped virus of recently prevalent JN.1 strain (IC₅₀, 12.74 nM). We found that the parental antibodies showed weak or no binding to the receptor binding domain (RBD) of the SARS-CoV, EG.5.1, and JN.1. However, the 5-HI maintained the binding with RBD and prevented the binding between hACE2 and RBD (IC₅₀ for the RBD of SARS-CoV, 1.067 nM; EG.5.1, 0.423 nM; JN.1, 0.223 nM). In neutralization assays with the authentic virus, we found that the 5-HI effectively neutralized Omicron variants XBB.1.5 (IC₅₀, 0.308 nM), EG.5.1 (IC₅₀, 0.129 nM), and JN.1 (IC₅₀, 13.692 nM), while its parental antibodies showed weakened or no neutralization. Therefore, the 5-HI represents a promising candidate for further development in the treatment and prevention of ongoing evolved SARS-CoV-2 VOCs and other SARSr-CoVs that potentially emerge in the future.

30 Oct 2024·Journal of the American Chemical Society

Rapid Systematic Screening of Bispecific Antibody Surrogate Geometries for T-Cell Engagement Using DNA Nanotechnology

Article

Author: Greschner, Andrea A. ; Messaoudi, Sabrine ; Baniahmad, Seyed Farzad ; Craig, Morgan ; Gauthier, Marc A. ; Wylie, Ryan G. ; Durocher, Yves ; Marple, April ; Pelletier, Marianne ; Wai, Kevin

Bispecific antibodies (bsAbs) are emerging immune-therapeutics, and many formats exist that differ considerably in structure. However, little systematic data exist about how the spatial organization of their components influences activity, requiring innovative approaches combining empirical and quantitative frameworks. This study presents a modular DNA nanotechnology platform to generate numerous bsAbs with surrogate geometries that span the structural features of the BiTE, IgG-like, and IgG-conjugate platforms to screen for T-cell engagement. Results highlight interesting structure-activity relationships regarding bsAb potency and selectivity and raise questions regarding the molecular phenomena underlying activity. To elucidate some effects, the platform was paired with a simple mathematical model. This work is thus one of the first to systematically investigate and reveal the importance of the spatial organization of bsAb components on activity and equally provides an accessible and convenient tool for rapidly mapping out such trends for other combinations of target epitopes.

01 Oct 2024·Cellular Oncology

A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells

Article

Author: Gu, Runxia ; Wang, Min ; Wang, Jianxiang ; Yan, Zhifeng ; Xing, Haiyan ; Tang, Kejing ; Rao, Qing ; Chen, Nianci ; Tian, Zheng ; Qiu, Shaowei ; Ma, Haotian ; Xu, Yingxi ; Zhang, Ting

BACKGROUNDImmunotherapies, including chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs), encounter several challenges in the management of acute myeloid leukemia (AML), including limited persistence of these treatments, antigen loss and resistance of leukemia stem cells (LSCs) to therapy.METHODSHere, we proposed a novel dual-targeting approach utilizing engineered anti-IL10R CAR-T cells to secrete bispecific antibodies targeting CD33. This innovative strategy, rooted in our previous research which established a connection between IL-10 and the stemness of AML cells, designed to improve targeting efficiency and eradicate both LSCs and AML blasts.RESULTSWe first demonstrated the superior efficacy of this synergistic approach in eliminating AML cell lines and primary cells expressing different levels of the target antigens, even in cases of low CD33 or IL10R expression. Furthermore, the IL10R CAR-T cells that secret anti-CD33 bsAbs (CAR.BsAb-T), exhibited an enhanced activation and induction of cytotoxicity not only in IL10R CAR-T cells but also in bystander T cells, thereby more effectively targeting CD33-positive tumor cells. Our in vivo experiments provided additional evidence that CAR.BsAb-T cells could efficiently redirect T cells, reduce tumor burden, and demonstrate no significant toxicity. Additionally, delivering bsAbs locally to the tumor sites through this strategy helps mitigate the pharmacokinetic challenges typically associated with the rapid clearance of prototypical bsAbs.CONCLUSIONSOverall, the engineering of a single-vector targeting IL10R CAR, which subsequently secretes CD33-targeted bsAb, addresses the issue of immune escape due to the heterogeneous expression of IL10R and CD33, and represents a promising progress in AML therapy aimed at improving treatment outcomes.

100 Deals associated with Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Discovery	CN	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Tumour associated antigen targeting bispecific antibody(PersonGen Biotherapeutics)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation